Single-cell Omics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, Single-Cell Metabolomics), By Application (Oncology, Cell Biology, Neurology, Immunology), By End-User (Pharmaceutical & Biotechnology Companies, Academic and Research Organizations, Hospital and Diagnostic Laboratories, Others), By Region and Competition, 2019-2029F

Market Overview

Global Single-cell Omics Market was valued at USD 1.42 Billion in 2023 and is expected to reach USD 2.10 Billion by 2029 with a CAGR of 6.87% during the forecast period. Single-cell Omics are collection of cutting-edge technologies and methodologies used to analyze the molecular characteristics of individual cells on a large scale. Traditional omics techniques, such as genomics, transcriptomics, proteomics, and metabolomics, involve studying the collective properties of a large population of cells. In contrast, single-cell omics allows researchers to examine the genetic, transcriptomic, proteomic, and other molecular profiles of single cells, providing insights into cellular heterogeneity, function, and behavior at an unprecedented level. The field of single-cell omics has gained significant importance and recognition due to its ability to uncover cellular diversity within a tissue or sample, as well as its applications in various scientific and medical contexts. Some key components of single-cell omics are following : Single-Cell Genomics, Single-Cell Transcriptomics, Single-Cell Proteomics, Single-Cell Metabolomics. Applications of Single-Cell Omics: Disease Research, Drug Discovery and Development, Personalized Medicine and developmental biology.

Key Market Drivers

Advances In Single-Cell Technologies Drives The Market Growth

Advances in single-cell technologies play a crucial role in driving the growth of the global single-cell omics market. These technological innovations have expanded the capabilities, efficiency, and accessibility of analyzing individual cells at the molecular level, leading to a wide range of applications in research, diagnostics, drug discovery, and personalized medicine. For instance, In 2022, the Center for Drug Evaluation and Research (CDER) authorized 37 novel drugs, encompassing both new molecular entities (NMEs) submitted through New Drug Applications (NDAs) and new therapeutic biological products approved under Biologics License Applications (BLAs). The active ingredient(s) in these novel drugs had not previously received approval in the United States.

Technological advancements have enabled the simultaneous analysis of a larger number of individual cells. High-throughput single-cell sequencing platforms and microfluidic devices allow researchers to process and analyze thousands to millions of cells in a single experiment. This increased throughput accelerates research and allows for more comprehensive cell profiling. Improved single-cell technologies provide higher sensitivity and resolution, enabling the detection of rare cell populations, low-abundance molecules, and subtle molecular variations. This is particularly important for understanding cellular heterogeneity and identifying rare cell types involved in disease. Advances in single-cell technologies have enabled the integration of multiple omics data types from the same individual cells, such as simultaneous analysis of transcriptomics, genomics, and proteomics. This comprehensive approach provides a more holistic view of cellular function and molecular interactions. Emerging spatial omics techniques allow researchers to analyze the molecular composition of individual cells within their tissue context. This spatial information is crucial for understanding cell-cell interactions, tissue organization, and disease mechanisms.

Growing Focus On Precision Medicine Drives The Market Growth

The growing focus on precision medicine is a significant driver of the growth of the global single-cell omics market. Precision medicine aims to customize medical treatments and interventions based on individual patient characteristics, including genetic makeup, molecular profiles, and other relevant factors. Single-cell omics technologies provide a powerful toolset to achieve the goals of precision medicine by enabling in-depth analysis of individual cells and uncovering the molecular basis of diseases and patient variability. Single-cell omics allows researchers to characterize the molecular signatures of individual cells, which can help identify specific disease markers, drug targets, and treatment response predictors at a personalized level. This information guides the development of targeted therapies tailored to individual patients, driving the demand for single-cell analysis technologies. In November 2022, The Texas A&M University System was awarded a $1.19 million grant from the National Institutes of Health (NIH) to support a multidisciplinary collaboration exploring the complex relationships between genomics, nutrition, and health. This research aims to enhance the diagnosis and treatment of cancer and other diseases. The project focuses on advancing single-cell data science, which examines variations in genes and gene expression among individual cells within an organism. Since cancer originates from genetic abnormalities in specific cells, scientists anticipate that single-cell data science will uncover critical medical insights.

Precise identification of disease-specific markers and biomarkers is crucial for early disease detection and accurate diagnosis. Single-cell omics enables the identification of rare or subtle molecular changes that may serve as biomarkers for specific diseases, enhancing diagnostic accuracy. Many diseases, including cancer, exhibit cellular heterogeneity, where different cells within a tissue or tumor may respond differently to treatment. Single-cell omics helps reveal this heterogeneity, enabling the design of therapies that target specific cell populations. Single-cell omics provides insights into the intricate molecular mechanisms underlying diseases. This understanding is essential for developing precise interventions that address the root causes of diseases and minimize side effects.

Download Sample Report

Key Market Challenges

Data Complexity and Interpretation

Analyzing single-cell omics data requires advanced bioinformatics skills and tools. Researchers and analysts must be proficient in data preprocessing, quality control, normalization, dimensionality reduction, clustering, and differential expression analysis. The shortage of skilled bioinformaticians can hinder the effective use of single-cell omics technologies. Developing robust algorithms for single-cell data analysis is a complex task. As new techniques and platforms emerge, novel algorithms are needed to address the unique characteristics of each technology. Algorithm development requires expertise in computational biology and statistics. Single-cell omics data can be affected by technical variability, including batch effects that arise from different experimental runs. Proper normalization methods and batch effect correction are essential to ensure that true biological signals are not masked by technical artifacts.

Sample Preparation Variability

Sample preparation variability is a significant challenge in the global single-cell omics market. Sample preparation is a critical step that directly impacts the quality, reproducibility, and accuracy of single-cell omics data. Inconsistencies or errors during sample preparation can introduce technical artifacts that obscure true biological signals and lead to unreliable results. Variability in cell viability and quality can result from differences in tissue dissociation, cell isolation, and handling procedures. Viability and quality directly affect the molecular profiles obtained from single cells, influencing downstream analysis and interpretation. The choice of cell isolation technique (e.g., microfluidics, FACS, laser capture microdissection) can introduce variability in cell selection and recovery rates. Each technique has its own limitations and biases that need to be considered. The efficiency of cell lysis and nucleic acid amplification can vary between samples, leading to differences in the quantity and quality of genetic material available for downstream analysis.

Ethical and Regulatory Considerations

Ethical and regulatory considerations pose important challenges to the global single-cell omics market. As the field of single-cell omics advances and its applications become more widespread, various ethical and regulatory issues need to be carefully addressed to ensure responsible and ethical use of these technologies. Collecting human samples for single-cell omics research raises issues related to informed consent and privacy. Participants must be informed about the scope of analysis, potential findings, and how their data will be used. Ensuring that participants fully understand the implications of single-cell omics studies is essential. Single-cell omics research often involves the use of clinical samples from patients, which raises questions about the ethical handling of these samples, especially when they are obtained during medical procedures for purposes unrelated to research. Single-cell omics data are valuable resources that can contribute to scientific knowledge and medical advancements. Balancing the sharing of data for the greater good while protecting patient privacy and data security is a challenge.

Key Market Trends

Clinical Translation and Biomarker Discovery

Clinical translation and biomarker discovery represent important trends in the global single-cell omics market. These trends highlight the increasing application of single-cell omics technologies in clinical research and healthcare, with a focus on improving disease diagnosis, patient stratification, and personalized treatment approaches. Single-cell omics allows researchers to identify distinct cell populations within complex tissues or tumors. This capability is particularly valuable for stratifying patients based on the molecular characteristics of their disease, enabling more precise and targeted treatment strategies. Single-cell omics technologies enable the discovery of novel biomarkers that can serve as indicators of disease presence, progression, or treatment response. These biomarkers can be used for early detection, prognosis, and monitoring of diseases. The ability to analyze individual cells at the molecular level supports the development of personalized treatment plans. By understanding the unique molecular profiles of patients, clinicians can tailor therapies to match the specific characteristics of each individual, optimizing treatment outcomes and minimizing side effects. Single-cell omics helps uncover specific cellular targets that play a key role in disease development and progression. This information is essential for the development of targeted therapies that address the underlying molecular mechanisms of diseases. Single-cell omics technologies provide insights into how individual cells respond to potential therapeutic compounds. This knowledge can accelerate drug development by identifying compounds with the highest likelihood of success and predicting patient responses in clinical trials.

Growing Biotechnology & Biopharmaceutical Industries Drives the Market Growth

The growing biotechnology and biopharmaceutical industries play a significant role in driving the growth of the global single-cell omics market. These industries are at the forefront of research and development in life sciences and healthcare, and their increasing demand for advanced technologies and tools, such as single-cell omics, has contributed to the expansion of the market. Biotechnology and biopharmaceutical companies are actively engaged in the discovery and development of new drugs and therapies. Single-cell omics technologies provide valuable insights into disease mechanisms, cellular responses, and potential drug targets, which aid in the identification and validation of drug candidates. Single-cell omics enables the identification and validation of novel therapeutic targets at a cellular and molecular level. This information is crucial for biotech and pharmaceutical companies seeking to develop innovative drugs that target specific cell types or disease-associated molecular pathways. Biotech and pharma industries are often focused on identifying biomarkers that can guide clinical trials, patient stratification, and treatment monitoring. Single-cell omics helps uncover biomarkers with high specificity and sensitivity, enhancing the accuracy of patient selection and treatment evaluation. Biotech and pharma companies are increasingly adopting personalized medicine approaches. Single-cell omics provides the necessary molecular insights to design more targeted clinical trials, stratify patients based on their individual profiles, and assess treatment responses more accurately. The development of companion diagnostics, which are tests that help determine the most suitable treatment for individual patients, is a key focus of the biopharmaceutical industry. Single-cell omics technologies contribute to the discovery of biomarkers that can be used for companion diagnostics.

Segmental Insights

Product Type Insights

In 2023, the Single-cell Omics market was dominated by the single-cell genomics and is predicted to continue expanding over the coming years. Single-cell genomics was one of the pioneering applications within the field of single-cell omics. The development of single-cell genomic sequencing techniques, such as single-cell RNA sequencing (scRNA-seq), revolutionized our ability to study gene expression at the single-cell level. Single-cell genomics has applications across diverse fields, including cancer research, developmental biology, immunology, neuroscience, and more. This versatility has led to its widespread adoption in various research areas. It allows researchers to uncover the heterogeneity present within cell populations, revealing distinct cell types, states, and trajectories. This information is crucial for understanding disease mechanisms and developmental processes. The segment is projected to experience the highest compound annual growth rate (CAGR) from 2025 to 2029.

Application Insight

In 2023, the Single-cell Omics market was dominated by oncology segment and is predicted to continue expanding over the coming years. Single-cell omics allows researchers to study the heterogeneity of tumor cells within a single tumor sample. This insight has profound implications for understanding tumor evolution, drug resistance, and the development of targeted therapies. It also enables the reconstruction of clonal evolution and tumor progression, helping to unravel the genetic and molecular changes that occur as cancer develops and spreads and identify rare subpopulations of cells within a tumor that may be responsible for therapy resistance or disease recurrence. Targeting these populations can improve treatment outcomes.

Download Sample Report

Regional Insights

The North America region has established itself as the leader in the Global Single-cell Omics Market. North America is home to numerous world-renowned academic and research institutions that have been at the forefront of single-cell omics research. These institutions have access to cutting-edge technology, expertise, and funding, allowing them to drive innovation in the field. The region hosts major biotechnology and life sciences hubs, such as the San Francisco Bay Area, Boston, and San Diego. These hubs foster collaboration, investment, and the development of novel single-cell omics technologies and products. Also, this region is home to a significant number of biotechnology and pharmaceutical companies that are actively involved in developing and commercializing single-cell omics technologies for research and clinical applications. 

Recent Developments

• On October 14, 2024, BD (Becton, Dickinson and Company), a global leader in medical technology, announced the commercial launch of the first high-throughput, robotics-compatible reagent kit designed to automate and enhance the efficiency and consistency of large-scale single-cell discovery studies. Developed through a collaboration between BD and Hamilton, this automated solution streamlines traditionally manual processes and accelerates the preparation of materials for genetic sequencing. The offering includes the newly launched BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform.
• In April 2023, Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced a collaboration with Fulgent Genetics, a technology-driven company with established clinical diagnostics and therapeutic development operations. Under this agreement, Fulgent Genetics has integrated single-cell multi-omics capabilities using the Tapestri Platform into its customizable service offerings, which include whole genome and exome sequencing, RNA sequencing, tumor profiling, methylation sequencing, liquid biopsy, single-cell sequencing, spatial biology, and pathology services. This expansion aims to address the growing demands of Fulgent Genetics' pharmaceutical clients. Furthermore, Fulgent Genetics will assess the Tapestri Platform for clinical development applications, aiming to streamline drug development and approval processes. 

Key Market Players

• Danaher Corporation
• CYTENA GmbH
• 10x Genomics Inc
• Becton, Dickinson and Company
• Cellenion SASU
• PerkinElmer Inc.
• ANGLE plc
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Mission Bio, Inc.

Report Scope:

In this report, the Global Single-cell Omics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Single-cell Omics Market, By Product Type:

o   Single-Cell Genomics

o   Single-Cell Transcriptomics

o   Single-Cell Proteomics

o   Single-Cell Metabolomics

• Single-cell Omics Market, By Application:

o   Oncology

o   Cell Biology

o   Neurology

o   Immunology

• Single-cell Omics Market, By End-User:

o   Pharmaceutical & Biotechnology Companies

o   Academic and Research Organizations

o   Hospital and Diagnostic Laboratories

o   Others

• Single-cell Omics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Single-cell Omics Market.

Available Customizations:

Global Single-cell Omics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Single-cell Omics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]